Search - tctmd.com

Displaying 141 - 160 of 311

Sort: Relevancy | Date

Presentation TCT 2017

The LDL Hypothesis Post FOURIER: Heading Home From ODYSSEY

Presenter: Bernard J. Gersh, Robert A. Harrington, Wolfgang Koenig

October 30, 2017

Presentation TCT 2017

Should Alleviating ISCHEMIA Be the Goal?

Presenter: Bernard J. Gersh, Robert A. Harrington, David J. Moliterno

October 30, 2017

Presentation TCT 2017

Primary Prevention in High Risk Patients II: THEMIS

Presenter: Bernard J. Gersh, Robert A. Harrington

October 30, 2017

Presentation TCT 2017

Primary Prevention In High Risk Patients I: REPRIEVE

Presenter: Bernard J. Gersh, Robert A. Harrington, Pamela S. Douglas

October 30, 2017

Presentation

Characterization of the Average Daily Ischemic and Bleeding Risk After Primary PCI for STEMI

October 03, 2017

Presentation CHIP Seattle 2017

Yes, the Data Favor Invasive Management and Revascularization for These Patients (with Ischemic CM)

Presenter: Ajay J. Kirtane

August 10, 2017

Presentation CHIP Seattle 2017

Ischemic Cardiomyopathy: Medical Therapy and Devices

Presenter: Ryan C. Martin

August 10, 2017

Presentation

Selection of Patients for Intra-arterial Treatment for Acute Ischemic Stroke

May 15, 2017

Presentation Fellows 2017

Rationale for Revascularization in Stable Ischemic Heart Disease

Presenter: Sahil A. Parikh, Ajay J. Kirtane

April 08, 2017

Presentation ECHO 2017

ASE Guidelines: The Clinical Use of Stress Echocardiography in Non-Ischemic Heart Disease

Presenter: Rebecca T. Hahn

April 01, 2017

AEGIS-I Trial: The Safety and Tolerability of CSL112

Presentation AHA 2016

The Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Human ApoA-I, After Acute Myocardial Infarction: The ApoA-I Event reducingG in Ischemic Syndromes I Trial (AEGIS-I)

Presenter: Michael Gibson

November 15, 2016

Presentation Cardiovascular Interventions 2016

Will CT-FFR Radically Change Our Approach to the Patient with Ischemic Heart Disease?

Presenter: Jorge A. Gonzalez

November 08, 2016

Presentation TCT 2016

Delivery System and Therapeutic Challenges and Opportunities in Africa

Presenter: Graham A. Cassel, Harun A Otieno

November 01, 2016

Presentation TCT 2016

Hot Topic #3: Anti-ischemic Therapy: Beta Blockers, ACE Inhibitors, and Ranolazine - Are They Effective?

Presenter: Bernard J. Gersh, Felix Mahfoud, Ori Ben-Yehuda

November 01, 2016

Presentation TCT 2016

Trial #7 - The Essentials ofCTSN SMR Trial - Two-Year Outcomes Following Mitral Valve Repair or Replacement for Severe Ischemic Mitral Regurgitation

Presenter: William A. Gray, Stephan Windecker, Michael Argenziano

October 31, 2016

Presentation TCT 2016

TCT 94: Impact of Thin-Cap Fibroatheromas on Unanticipated Ischemic Events in Medically Treated Patients With Diabetes Mellitus: Insights From the PROSPECT Study

Presenter: Farouc Jaffer, Amir Lerman, Elvin Kedhi

October 31, 2016

Presentation TCT 2016

Role of Papillary Muscle Relocation in Ischemic Mitral Valve Regurgitation

Presenter: Michael J. Mack, Francesco Maisano, Marco Moscarelli

October 30, 2016

Presentation TCT 2016

A Case Series of Ischemic and Nonischemic Leg Ulcers

Presenter: Koen Deloose, Jihad A. Mustapha, Ethan C Korngold

October 30, 2016

Presentation TCT 2016

LV Volume Reduction in Post-AMI, Ischemic Heart Failure Patients

Presenter: Oscar A. Mendiz, Giora Weisz, Horst Sievert

October 30, 2016

Presentation ESC 2016

Safety and Preliminary Efficacy of Intravenous Allogeneic Mesenchymal Stem Cells in Patients With Non-ischemic Heart Failure

Presenter: Javed Butler

August 28, 2016

Advertisement

The LDL Hypothesis Post FOURIER: Heading Home From ODYSSEY

Should Alleviating ISCHEMIA Be the Goal?

Primary Prevention in High Risk Patients II: THEMIS

Primary Prevention In High Risk Patients I: REPRIEVE

Characterization of the Average Daily Ischemic and Bleeding Risk After Primary PCI for STEMI

Yes, the Data Favor Invasive Management and Revascularization for These Patients (with Ischemic CM)

Ischemic Cardiomyopathy: Medical Therapy and Devices

Selection of Patients for Intra-arterial Treatment for Acute Ischemic Stroke

Rationale for Revascularization in Stable Ischemic Heart Disease

ASE Guidelines: The Clinical Use of Stress Echocardiography in Non-Ischemic Heart Disease

The Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Human ApoA-I, After Acute Myocardial Infarction: The ApoA-I Event reducingG in Ischemic Syndromes I Trial (AEGIS-I)

Will CT-FFR Radically Change Our Approach to the Patient with Ischemic Heart Disease?

Delivery System and Therapeutic Challenges and Opportunities in Africa

Hot Topic #3: Anti-ischemic Therapy: Beta Blockers, ACE Inhibitors, and Ranolazine - Are They Effective?

Trial #7 - The Essentials ofCTSN SMR Trial - Two-Year Outcomes Following Mitral Valve Repair or Replacement for Severe Ischemic Mitral Regurgitation

TCT 94: Impact of Thin-Cap Fibroatheromas on Unanticipated Ischemic Events in Medically Treated Patients With Diabetes Mellitus: Insights From the PROSPECT Study

Role of Papillary Muscle Relocation in Ischemic Mitral Valve Regurgitation

A Case Series of Ischemic and Nonischemic Leg Ulcers

LV Volume Reduction in Post-AMI, Ischemic Heart Failure Patients

Safety and Preliminary Efficacy of Intravenous Allogeneic Mesenchymal Stem Cells in Patients With Non-ischemic Heart Failure

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content